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Background: The return of extracorporeal circuit blood at the termination of cardiopulmonary bypass (CPB) is an
important feature of blood conservation during cardiac surgery procedures globally. We report our initial clinical
evaluation of the Hemobag system a blood-salvaging device designed for whole blood recovery of residual
post-CPB volume.
Methods: Residual whole blood is hemoconcetrated through the multipass “recovery loop” circuit separate from
the CPB and collected in the Hemobag System. This allows the surgeons to continue with surgery, decannulate,
and administer protamine simultaneously while the Hemobag is in use and the CPB circuit remains safely primed.
We have compared 25 patients receiving the Hemobag to a control group of 25 patients treated with the cell
washer that represented our previous standard of care method of circuit blood-salvaging technique.
Results: The Hemobag system provided significantly higher hemoglobin, hematocrit, fibrinogen, albumin, and total
protein levels in the final product reducing the amount of wasted autologous blood cells. There were no
device-related complications. There were no significant differences in terms of blood utilization, chest tube
drainage and clinical outcomes over the entire postoperative period among groups.
Conclusions: These results suggest that the Hemobag system is a safe and efficient method to multipass
hemoconcentrate the residual diluted blood of the CPB circuit. The Hemobag has demonstrated its ability to
maximize the composition of the residual CPB volume to achieve the best possible post-CPB hemoglobin, plasma
protein and coagulation factors profile for the patient respect to CW.
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Cardiac surgery is one of the leading consumers of blood
products. Intraoperative and postoperative blood losses
are predictable contributors to this problem. A less com-
monly recognized factor is the effect of hemodilution of
the patient by the pump prime of cardiopulmonary by-
pass (CPB) circuit.
Blood conservation and fluid management are now the
most important issues surrounding cardiac surgery
today. Recent data independently link allogeneic blood
use to increase morbidity and mortality after CPB [1,2].* Correspondence: colli.andrea.bcn@gmail.com
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reproduction in any medium, provided the orFollowing termination of bypass, the CPB circuit con-
tains a significant volume of diluted blood. The CPB is
capable of containing a significant amount of diluted re-
sidual autologous whole blood. Commonly, this residual
blood is discarded or only partially salvaged for a num-
ber of reasons including 1) the blood is excessively di-
lute, 2) it contains a significant amount of activated
mediators, and 3) the notion that the platelets are dys-
functional and subsequently impair overall coagulation
status [2,3].
Published data have shown that most of the ill effects
of CPB on platelets and other coagulation factors are
temporary and reversible within hours post-operatively
[4]. The hemodilution encountered during cardiac sur-
gery can be corrected through hemoconcentration [5].
Various methods have been used to salvage this blood,
including centrifugation/washing, direct transfusion and
ultrafiltration both on-CPB and post-CPB. The. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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product that is free of plasma proteins, coagulation fac-
tors, and platelets [5].
The direct infusion into the patient cause hemodilu-
tion and volume overload, contributing to organ edema
and organ dysfunction and requiring vasodilatation and
diuretic therapy to control these negative effects that
can last 4–8 hours postoperatively. Subsequently, this
can create further hemodynamic instability and electro-
lyte imbalance [6].
Alternatively ultrafiltration has the advantage of re-
moving excess water volume, which has been shown to
improve, hematocrit, arterial oxygen content concentra-
tion of coagulation factors, and decreasing tissue edema
and organ dysfunction [7]. Low molecular weight com-
ponents, which may include cytokines and toxins, are
also removed owing to the membrane pore size, thus po-
tentially decreasing perioperative inflammation [8].
Ultrafiltration during CPB and post-CPB has evolved into
different techniques along decades such as zero-balance
ultrafiltration and modified ultrafiltration. Established ultra-
filtration techniques are time consuming, requiring the can-
nulae to remain in the patient during the entire process,
and thus delaying the reversal of heparinization.
The Hemobag system (Global Blood resources LLC,
Somers, CT) has been developed to offset the difficulties
associated with standard ultrafiltration techniques.
We report our initial evaluation and clinical experi-
ence with the Hemobag ultrafiltration system.Figure 1 Hemobag kit components.Methods
Study population
Consecutive patients scheduled for elective cardiac sur-
gery with the use of CPB at the Hospital Universitari
Germans Trias i Pujol, Badalona, Spain, were selected.
Patients were divided into the Hemobag group (Group
H) and in the Cell washer group (Group CW) according
to the Surgeon preference. We included patients who
were undergoing CABG surgery or cardiac valve replace-
ment or repair, alone or in combination. Exclusion cri-
teria were: patients over 80 years old, redo or emergency
surgery, endocarditis or pericardic disease.
We have compared 25 patients receiving the Hemobag
(Group H) to a matched control group of 25 patients
treated with the CW that represented at that time our
standard of care method to process the residual CPB cir-
cuit blood.
At the end of surgery all remaining blood inside the
CPB circuits was recovered and concentrated by the CW
(Electa, Sorin group, Saluggia, Italy) if patient was in
Group CW. In case patient was in Group H, the
remaining blood was recovered and ultrafiltrated using
the Hemobag System.
In the Group H all blood in the surgical field was aspi-
rated only using the cardiotomy suction and in Group
CW was aspirated using both the CW and the cardiot-
omy suction. All blood was recovered and concentrated/
ultrafiltrated before starting protamine. After reinfusion
of the recovered blood an extra dose of protamine (20%
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The cardiopulmonary bypass protocol and equipment
used were identical for all patients enrolled in the study.
Local review board approved the study. Written
informed consent was obtained from the patients. The
present clinical research was carried out in compliance
with the Helsinki Declaration.
Technology
The Hemobag system received is commercially available
in Europe, United States of America and Canada. The
Hemobag recovers autologous whole blood at the end of
CPB with all the cells and proteins still intact. The
Hemobag system concentrates the residual CPB volume
with multipass hemoconcentration to a target volume orFigure 2 Diagram of the “Recovery loop”, a sterile and isolated circui
hemoconcentrator) to ultrafiltrate the post Cardiopulmonary bypass
concentrate blood in the Hemobag mediated by a roller pump.target hematocrit decided by the surgical team. The CPB
is always maintained safely primed and ready to immedi-
ately go back on bypass if there is an emergency. The
Hemobag circuit is separate from the CPB circuit. This
allows the surgeons to continue with surgery, decannu-
late, and administer protamine simultaneously while the
Hemobag is in use.
The Hemobag system kit is composed of the Hemo-
bag, the TS3 tubing set (Global Blood Resources), and
hemoconcentrator (Minntech HPH 1400; Minneapolis,
MN) Figure 1.
The Hemobag reservoir is filled with the residual
blood of the CPB reservoir and connected to the “Recov-
ery loop”. The recovery loop consist in the connection
of the Hemobag, the TS3 tubing set, the pressuret (Hemobag, TS3 tubing set, pressure manometer and
whole blood. The system use a multi-pass ultrafiltration technique to








Mean age (years) 65.5 ± 12.7 64.9 ± 12.1 0.865
Female 10 (40%) 10(40%) 1.000
Diabetes mellitus 9 (36%) 8 (32%) 0.765
Dislipemia 13 (52%) 15 (60%) 0.569
Hypertension 18 (72%) 17 (68%) 0.758
Peripheral vascular disease 3 (12%) 4 (16%) 1.000
Respiratory disease 4 (16%) 3 (12%) 1.000
Stroke 1 (4%) 0 1.000
NYHA III–IV class 16 (64%) 17 (68%) 0.765
Atrial fibrillation 5 (20%) 7 (28%) 0.508
Severe pulmonary
hypertension (>59 mmHg)
2 (8%) 2 (8%) 1.000
Ejection fraction 57.8 ± 22 57.9 ± 32 0.990
Logistic EuroSCORE (%) 6.9 ± 8 7.5 ± 8.3 0.796
NYHA, New York Heart Association.








Cardiopulmonary bypass time (min) 89.5 ± 46.1 93.1 ± 45.3 0.782
Cross-clamp time (min) 63.3 ± 36.1 65.7 ± 39.4 0.823
Hours of intubation 2.6 ± 1.9 2.3 ± 2.0 0.589
24 h postoperative bleeding (ml) 462 ± 336 538± 430 0.490
Length of stay in ICU (days) 1.5 ± 2.9 1.5 ± 1.9 1.000
Total length of stay (days) 11.1 ± 10.1 11.6 ± 8.8 0.853
Hemoglobin at discharge (g/dl) 11.5 ± 1.2 10.7 ± 2.0 0.093
Death 1 (4%) 1 (4%) 1.000
Mean quantity of blood reinfused (ml) 461 ± 174 410± 132 0.249
Patients receiving blood transfusion 9 (36%) 11 (44%) 0.564
Patients receiving platelet transfusion 3 (12%) 5 (20%) 0.702
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that is not in use after discontinuing CPB (Figure 2).
The “recovery loop” creates a sterile, and isolated circuit
concentrating the whole blood into the Hemobag. Aver-
age flows are maintained around 450 mL/min, with a
maximum transducer pressure of 325 mmHg. No suc-
tion is required to facilitate effluent removal.
Statistical analysis
The Hemobag and the CW groups were compared in
terms of clinical characteristic and surgical outcomes by
using the Chi-square test (or the Fisher exact test when ap-
propriate) for categorical variables and the t test for con-
tinuous variables. The significance level was set at 0.05.
In order to compare the Hemobag and the CW sys-
tems, the differences in hematocrit, platelet count, total
protein concentration, albumin and fibrinogen values be-
tween pre and post treatment were calculated, both in
the Hemobag and the CW groups.
Results and discussion
Mean age was 65.7 ± 12.3 years with 40% of females
(n = 25). Patients in both groups presented similar base-
line clinical characteristics (Table 1). Thirty patients
(60%) underwent heart valve surgery, fifteen patients
(30%) underwent coronary artery bypass graft and ten
patients (10%) underwent combined heart valve surgery
and coronary artery bypass graft. The distribution of sur-
geries was equivalent in both groups.
Surgical mortality was 4% (n= 2). One patient died of
heart failure and one died of a stroke. There was no
death during 30-day follow-up. There was no bleeding
re-exploration.
The rates of major and minor postoperative morbidity
were comparable among the groups. The use of vaso-
pressor support in the ICU, were also similar among
groups. Mean quantity of blood recovered and reinfused
to the patient with the Hemobag device was
461 ± 174 ml and 410 ± 132 ml with the CW device
(p = 0.249).
The number of blood bags transfused in the operating
theater, the ICU and in the ward were similar in both
groups (Table 2).
We have observed a global improvement of all the
blood parameters analyzed in the transfusion bags be-
fore and after processing in the Hemobag group re-
spect to the CW group (Table 3). In particular we have
observed that the hematocrit increased from 21%± 2%
to 51%± 3% in the Group H respect to the increase
from 21%± 3% to 35%± 3% in Group CW (p< 0.001).
The platelet count increase in Group H from
105 ± 12 K/mm3 to 201 ± 22 K/mm3 compared to the
decrease from 102 ± 11 K/mm3 to 57 ± 11 K/mm3 in
Group CW (p< 0.001). The total protein concentrationpassed from 3± 0.5 mg/dL to 9 ± 1 mg/dl in Group H
and dropped from 3± 0.3 mg/dL to 0.4 ± 0.2 mg/dL in
Group CW (p< 0.001). Albumin increased from
1.5 ± 0.3 mg/dL to 4.5 ± 0.3 mg/dL in Group H and
dropped from the same 1.7 ± 0.3 mg/dL to 0.3 ± 0.1 mg/
dL in Group CW (p< 0.001). Fibrinogen also increased
in Group H from 125±18 mg/dL to 342± 39 mg/dL
and decreased from 122±18 mg/dL to 33± 4 mgdL in
Group CW (p< 0.001).
As stated in recent published STS blood conservation
guidelines 2011 [9], general consensus suggests that
some form of pump salvage and reinfusion of residual
pump blood at the end of CPB is reasonable as part of a
blood management program to minimize blood transfu-
sion (Level of evidence C).
Table 3 Blood data pre and post hemoconcentration in the transfusion bags














Hematocrit (%) 21.52 (2.93) 51.4 (3.06) 29.88 (4.90) <0.001 21 (2.99) 34.88 (1.96) 13.88 (3.64) <0.001 <0.001
Platelets (n/mm3) 105.16 (12.92) 201.36 (22.28) 96.2 (29.04) <0.001 102.96 (11.18) 57.64 (11.73) −45.32 (17.23) <0.001 <0.001
Proteins (g/100 ml) 3.24 (0.40) 9.48 (1.01) 6.24 (1.11) <0.001 3.04 (0.36 0.48 (0.25) −2.56 (0.44) <0.001 <0.001
Albumin (g/100 ml) 1.55 (0.30) 4.47 (0.30) 2.92 (0.48) <0.001 1.74 (0.35) 0.32 (0.16) −1.42 (0.42) <0.001 <0.001
Fibrinogen
(mg/100 ml)
125.64 (18.20) 342.8 (39.83) 217.16 (50.62) <0.001 122.44 (18.12) 33.88 (3.96) −88.56 (18.61) <0.001 <0.001
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of residual pump blood is reasonable for minimizing post-
CPB allogenic RBC transfusion (Level of evidence A).
As showed in the STS guidelines there are several
studies in the literature that have compared the effects
of direct infusion of unprocessed post-CPB blood versus
centrifugation [10-17]. Despite limitations of the current
body of literature (small sample size, only CABG
patients), all studies have showed superiority of the
pump salvage strategy compared with no salvage of re-
sidual blood. In the literature there are only few reports
comparing the effectiveness of centrifugation with ultra-
filtration in concentrating post CPB blood to minimize
blood loss and transfusion requirements.
Boldt et al. [10] studied 40 nonrandomized patients
undergoing elective CABG procedures and discovered
no significant difference in blood loss or frequency of
donor blood transfusion between the centrifugation and
ultrafiltration groups.
Samolyk and coworkers [13] used a case-matched
control study to compare centrifugation and ultrafiltra-
tion in 100 patients; there was no difference in blood
utilization or postoperative bleeding between groups.
The results of the present study are in accordance
with those published previously. Similarly to Samolyk
et al. [13] we have analyzed the clinical and laboratory
parameters of the blood bags processed with the
Hemobag and conventional CW. We have not
observed differences in the clinical outcomes of both
groups but we have observed important differences in
the quality of concentrated blood reinfused to the pa-
tient. Ultrafiltration (Group H) of residual CPB blood
produced a protein-rich concentrated whole blood re-
spect to Centrifugation (Group CW) of residual CPB
blood that produced concentrated red cells mostly de-
void of plasma proteins.
Experimental studies by Delaney et al and Roeder et al.
[18,19] already showed that the Hemobag technique
yielded significantly higher hemoglobin, hematocrit, fi-
brinogen, albumin, and total protein levels in the final
hemoconcentrated product respect to the most common
of standard method of hemoconcentration.This report describes our initial evaluation and appli-
cation of the Hemobag system confirming that its use
offered an high quality hemoconcentrated blood. In our
Institution the multi-disciplinary and multi-modality
perioperative approach to blood conservation has be-
come a central aspect of our general strategy to improve
of our clinical results.
Part of this multi-modality approach is the hemo-
concentration of the residual whole blood in the ECC
post-CPB. This avoids the discard of plasma proteins,
coagulation factors, and platelets as typically seen with
cell washing techniques.
The introduction of the Hemobag system in our daily
practice has improved the quality of blood management
of our surgical procedures.
The Hemobag demonstrated to maximize the compos-
ition of the residual CPB volume to achieve a good post-
CPB hemoglobin, plasma protein and coagulation factors
profile for the patient. It also achieve the goal of salva-
ging and returning to the patient the autologous whole
blood volume offering all the benefits of an appropriate
colloid pressure at both macro and micro circulatory
domains in terms of oxygen delivery to cells and effect-
ive homeostasis.
The Hemobag like the CW works separately from the
CPB and allow surgery to continue uninterrupted while
the hemoconcentration process is ongoing and to adminis-
ter protamine. The CPB is maintained sterile, primed and
ready to resume CPB in case of emergency. An important
limitation observed for the Hemobag system respect to the
CW is that it needs more time (3–5 minutes) to hemocon-
centrate the same amount of residual blood post-CPB.
In our observational study the group of patients treated
with the Hemobag did not required higher vasopressor
support after weaning the CPB or in the postoperative
time, in contrast to the reported data in the literature of
patients treated with modified ultrafiltration [20]. This
may have occurred because the Hemobag ultrafiltration
system could be started when the patients was
hemodynamic stable after weaning from CPB.
The major limitation of the present preliminary insti-
tutional report is related to the non-randomized design
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There was no statistically significant difference in clinical
outcomes in the 2 groups because the trial was not pow-
ered for this. We consider that in the future larger ran-
domized controlled trials would help to better quantify
the overall postoperative benefits to surgical patients
and to better target the use of the Hemobag system for
patient stability and bleeding.
Conclusions
In summary, this preliminary institutional report demon-
strated that the Hemobag system is a safe and efficient
method to hemoconcentrate the residual diluted blood of
the CPB compared to the CW.
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